[A new approach to the therapy of pyoderma in servicemen: the use of the actoprotector bemitil].
At 51 men at the age from 20 till 30, sick with pyodermatitis, the clinical-immunological aspects and efficiency of-actoprotector, capable to support motor activity and human performance in the extreme environments. Bemitil has appeared more effective in comparison with conventional therapy: by general and combined application the parameters of immunity have been normalized statistically authentically, and at outside application-the places of damage were cleared faster, disappeared painfulness, hyperemia, edema, terms of staying in the hospital were reduced. The clinical recovery was in 86.3 +/- 4.8% of the patients, while effectiveness from conventional means was 62.1 +/- 6.8%.
A V
AV
Samtsov
G N
GN
Tarasenko
A V
AV
Smirnov
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D001562:Benzimidazoles / Q000627:therapeutic use*; D002908:Chronic Disease; D004341:Drug Evaluation; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008889:Military Personnel; D009824:Ointments; D011711:Pyoderma / Q000188:drug therapy* / Q000276:immunology; D012008:Recurrence; D012426:Russia; D013607:Tablets
D000276:Adjuvants, Immunologic; D001562:Benzimidazoles; D009824:Ointments; D013607:Tablets; C049825:bemethyl